Beyond CPAP

CPAP is the reference standard, but a meaningful share of people never tolerate it — and the alternative menu is longer than most assume. This page ranks the options for treating sleep apnea by the strength of the evidence behind each, from the best-supported to the genuinely experimental.

Why CPAP Needs Competition

CPAP's problem is not effectiveness — it is nightly use. Adherence studies consistently find a large share of users abandon the machine within the first year, and the parent topic covers the adherence battle in detail. That reality creates the real clinical question: when the best-tolerated effective option fails, what is second, third, and fourth? The honest framing for everything below: each option trades some effectiveness for some adherence — the right choice is the one you will actually use.

The Menu, Ranked by Evidence

Weight Loss: The Closest Thing to a Cure

Weight loss is the one option that attacks the mechanism rather than propping the airway open. The dose-response is well quantified: in the Wisconsin Sleep Cohort, a 10% weight gain predicted roughly a 32% increase in AHI, while a 10% loss predicted about a 26% decrease (Peppard et al., JAMA, 2000):

The trials tell the same story. A randomized controlled trial of a very low energy diet in obese men with moderate-to-severe OSA roughly halved the AHI and put a subset of participants into remission (Johansson et al., BMJ, 2009). In the modern era the GLP-1 receptor agonists have entered the picture: the SURMOUNT-OSA trials found tirzepatide produced large AHI reductions in adults with obesity and moderate-to- severe OSA — on the order of half or more of the baseline event rate, with a meaningful share of participants no longer meeting criteria for moderate-to-severe disease (Maldonado et al., NEJM, 2024). Two caveats keep this honest: the benefit tracks the weight, so stopping the drug usually means the apnea returns; and weight loss helps most, but not always completely — anatomy still matters (see Not just obesity). The Weight Loss protocol owns the how-to side of the ledger.

Mandibular Advancement Devices: The Main Alternative

A custom-fitted oral appliance holds the lower jaw and tongue forward during sleep, mechanically widening the airway. The AASM's guideline panel reviewed the trials and endorsed appliance therapy for OSA with appropriate titration by a qualified dentist (Ramar et al., J Clin Sleep Med, 2015). The honest comparison with CPAP: appliances reduce AHI less — meaningful for mild-to-moderate disease, often insufficient alone for severe — but people actually wear them, with adherence consistently reported as higher than CPAP in head-to-head studies. The trade sometimes nets out: a partial treatment used every night can beat a full treatment used rarely. Side effects are real but mostly reversible — tooth movement, bite changes, jaw discomfort — which is why the custom, dentist-titrated route matters more than the mail-order versions.

Positional Therapy: The Free Option Hiding in Plain Sight

For a large share of patients — estimates suggest half or more in some cohorts — the airway collapses mainly when lying on the back. For them, simply not sleeping supine is a treatment. The evidence base is modest but real: reviews of positional therapy find meaningful AHI reductions in position-dependent patients (Ravesloot et al., Sleep and Breathing, 2013). The practical problem is enforcement — people roll onto their backs without knowing it. The old tennis-ball-sewn-into-pajamas trick works but is miserable; modern wearable buzzers that vibrate when you roll supine are better tolerated. The catch: position-dependence should be documented (a home test that records position, or a lab study) before you build your strategy on it.

Myofunctional Therapy: Cheap, Safe, Modest

Structured daily exercises for the tongue, soft palate, and throat muscles — performed for months — show real but modest effects. A systematic review and meta-analysis of the trials found myofunctional therapy reduced AHI in adults, with effects concentrated in mild-to-moderate disease (Camacho et al., Sleep, 2015). Nobody should expect it to replace CPAP in severe OSA, but as an adjunct — or a first move in mild disease — it is essentially free of downside beyond the discipline of doing the exercises. Combined with positional therapy and weight loss, it belongs in the "stacking" logic below.

Hypoglossal Nerve Stimulation: The Implant Era

The most interesting recent addition is an implanted device that stimulates the hypoglossal nerve in rhythm with breathing, pushing the tongue forward with each breath. The pivotal STAR trial in CPAP-intolerant patients with moderate-to-severe OSA found large AHI reductions at one year — the median AHI fell by roughly two-thirds — and the response criteria were met by most participants (Strollo et al., NEJM, 2014). That is genuinely good, but the honest framing has three parts. First, selection matters enormously: the trial enrolled people whose collapse pattern the device could address, and real-world response is lower than pivotal-trial response. Second, it is surgery — an implanted device, with infection, battery, and discomfort considerations. Third, long-term data beyond a decade are still accruing. For the right patient it is transformative; for the wrong one it is an expensive near-miss.

Upper Airway Surgery: Last, for Good Reason

Traditional surgical approaches — removing tissue, tightening the palate — have the weakest average evidence. The classic meta-analysis of uvulopalatopharyngoplasty (UPPP) found roughly 40% of patients achieved the success threshold, with results highly dependent on anatomy (Sher et al., Sleep, 1996). Maxillomandibular advancement — moving the jaws forward — is more effective but far more invasive. The modern view: surgery is for specific, identifiable anatomical problems (huge tonsils, severe jaw deficiency) in patients who have failed the less invasive options — not a first move.

How to Choose: The Stacking Logic

The most useful mental model is that these options compose rather than compete:

• 🥇 Start with the root cause. Any excess weight makes every other option work better; 10% loss meaningfully lowers the AHI even before resolution.
• 🥈 Match the option to the anatomy. Supine-dominant? Positional therapy. Mild-to-moderate with a protrusible jaw? An appliance. CPAP-intolerant with the right collapse pattern? Consider stimulation.
• 🥉 Stack the small effects. Weight loss + appliance + myofunctional therapy + side-sleeping can sum to a large reduction where no single option would have sufficed.
• 🔁 Re-measure, don't assume. Every alternative deserves a follow-up study to confirm the AHI actually fell — treating on faith is how untreated disease persists under a new label. The Quarterly Audit habit applies here as anywhere.

Questions, Answered Briefly

• 🦷 Do mail-order mouthpieces work? Not reliably. The trial evidence is for custom-fitted, dentist-titrated devices. Off-the-shelf versions can worsen jaw issues and under-deliver — and an untitrated device may silence snoring while leaving the apnea untreated.
• 💉 Is tirzepatide a sleep apnea drug? It is a weight-loss drug with major OSA effects in people with obesity. Without sustained weight loss, the apnea benefit fades — treat it as one mechanism, not a standalone cure.
• 👅 Do the mouth exercises actually do anything? Modest, real AHI reductions in mild-to-moderate disease — useful in a stack, unlikely to carry severe OSA alone.
• ⚡ Who is the implant actually for? CPAP-intolerant adults with moderate-to-severe OSA and a collapse pattern the device can address — a decision made through formal sleep-lab evaluation, not a brochure.

Related Topics